HSCT characteristics
| Time period of HSCT | |
| <2010 | 5 (12.2) |
| ≥2010 | 36 (87.8) |
| Donor type | |
| Matched family | 18 (43.9) |
| Matched unrelated | 18 (43.9) |
| Mismatched related | 4 (9.8) |
| Mismatched unrelated | 1 (2.4) |
| Stem cell source | |
| PBSC | 21 (51.2) |
| Marrow | 20 (48.8) |
| Conditioning | |
| Treosulfan-based (42 g/m2) | 24 (58.5), 14 with thiotepa |
| Busulfan-based | 10 (24.4), AUC targeted in 6 |
| Melphalan-based | 7 (17.1) |
| Serotherapy | |
| Alemtuzumab | 22 (53.7) |
| ATG | 10 (24.4) |
| None | 9 (21.9) |
| GVHD prophylaxis | |
| CNI + MMF | 16 (39.0) |
| CNI + methotrexate | 7 (17.1) |
| CNI alone | 7 (17.1) |
| PTCy | 7 (17.1) |
| None | 4 (9.8) |
| Median CD34+ cell dose, ×106/kg | 6.2 (0.05-22.0) |
| Time period of HSCT | |
| <2010 | 5 (12.2) |
| ≥2010 | 36 (87.8) |
| Donor type | |
| Matched family | 18 (43.9) |
| Matched unrelated | 18 (43.9) |
| Mismatched related | 4 (9.8) |
| Mismatched unrelated | 1 (2.4) |
| Stem cell source | |
| PBSC | 21 (51.2) |
| Marrow | 20 (48.8) |
| Conditioning | |
| Treosulfan-based (42 g/m2) | 24 (58.5), 14 with thiotepa |
| Busulfan-based | 10 (24.4), AUC targeted in 6 |
| Melphalan-based | 7 (17.1) |
| Serotherapy | |
| Alemtuzumab | 22 (53.7) |
| ATG | 10 (24.4) |
| None | 9 (21.9) |
| GVHD prophylaxis | |
| CNI + MMF | 16 (39.0) |
| CNI + methotrexate | 7 (17.1) |
| CNI alone | 7 (17.1) |
| PTCy | 7 (17.1) |
| None | 4 (9.8) |
| Median CD34+ cell dose, ×106/kg | 6.2 (0.05-22.0) |
ATG, antithymocyte globulin; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; PBSC, peripheral blood stem cell; PTCy, posttransplant cyclophosphamide.